Page 30 - A9Rc19d2z_zddyc4_fc0.tmp

A randomised controlled trial evaluating the clinical and *Should Scotland provide whole genomic sequencing for
cost-effectiveness of a policy of freezing all embryos diagnosis of rare disorders: a health economic analysis
followed by thawed frozen embryo transfer, compared Investigators: Ryan, M., McKenzie, L., Hernández, R.,
with a policy of fresh embryo transfer in women Abbott, M. (HERU); Miedzybrodzka, Z., Mennie, L., Clark, C.
undergoing in-vitro fertilization (E-FREEZE) (Medical Genetics, University of Aberdeen); Heidenreich, S.
Investigators: Mahashwari, A. (NHS Grampian); Macklon, (Evidera).
N. (University of Southampton); Khalaf, Y. (Guy’s and St Source of Funding: Health Improvement, protection and
Thomas’s Hospital); Lavery, S. (Hammersmith Hospital); Services, Chief Scientist Office (CSO), University of Aberdeen
Child, T., Juszczak, E., Hardy, P., Kurinczuk, J. (University of and Chief Scientist Office (CSO) CORE.
Oxford); Rajkohwa, M. (Birmingham’s Women’s Hospital);
Coomarasamy, A. (University of Birmingham); Cutting, R. Technology Assessment Reviews (TARs) contract (2016–
(University of Sheffield); Brison, D. (Central Manchester 2022)
University Hospital NHS Trust); Troup, S. (Liverpool Women’s Investigators: Ramsay, C., Campbell, M., Brazzelli, M.,
Hospital); Lewis-Jones, C. (Infertility Network, UK); Raine- Cummins, E. (Health Services Research Unit, (HSRU), University
Fenning, N. (University of Nottingham); Bhattacharya, S. of Aberdeen); Scotland, G. (HERU/HSRU).
(Other Applied Health Sciences, University of Aberdeen); • *DAR: The ARCHITECT and Alinity urine NGAL assays,
Scotland, G. (HERU/HSRU). urine NephroCheck test, and urine and plasma
Source of Funding: National Institute for Health Research BioPorto NGAL tests to help assess the risk of acute
(NIHR), Health Technology Assessment (HTA) Programme and kidney injury for people who are being considered for
Chief Scientist Office (CSO) CORE. admission to critical care
• *Enzalutamide with androgen deprivation therapy for
*Recurrence of endometriosis: GnRH analogues versus treating metastatic hormone-sensitive prostate cancer
laparoscopic surgery trial (REGAL) (Single Technology Assessment)
Investigators: Saraswat, L. (NHS Grampian & University • Enzalutamide for treating non-metastatic hormone-
of Aberdeen); Scotland G. (HERU); MacLennan, G., Gillies, relapsed prostate cancer (Single Technology
K. (Health Services Research Unit, (HSRU), University of Assessment)
Aberdeen); Bhattacharya, S. (Other Applied Health Sciences, • Fast Track Appraisal: Risankizumab for treating
University of Aberdeen). moderate-to-severe plaque psoriasis
Source of Funding: National Institute for Health Research • Inotersen for treating hereditary transthyretin-related
(NIHR), Health Technology Assessment (HTA) Programme and amyloidosis. (Highly Specialised Technology)
Chief Scientist Office (CSO) CORE. • Lanadelumab for preventing recurrent attacks
of hereditary angioedema (Single Technology
Reducing Asthma Attacks in Children using Exhaled Nitric Assessment)
Oxide as a biomarker to inform treatment strategy – a • *Lorlatinib for previously treated ALK-positive
randomised controlled trial (RAACENO) advanced non-small-cell lung cancer (Single
Investigators: Norrie, J., Morgan, H. (Health Services Research Technology Assessment)
Unit, (HSRU), University of Aberdeen); Fielding, S., Price, D. • *TYRX Absorbable antibacterial envelope for
(Other Applied Health Sciences, University of Aberdeen); preventing infection from cardiac implantable
Scotland, G. (HERU/HSRU); Thomas, M. (University of electronic devices (Single Technology Assessment)
Southampton); Gaillard, E. (University of Leicester). Source of Funding: National Institute for Health Research,
Source of Funding: National Institute for Health Research Health Technology Assessment (HTA) Programme and Chief
(NIHR)/Medical Research Council (MRC), Efficacy & Mechanism Scientist Office (CSO) CORE.
Evaluation Programme and Chief Scientist Office (CSO) CORE.

30 HERU ANNUAL REPORT 2019